Ignite Creation Date:
2025-12-24 @ 5:23 PM
Ignite Modification Date:
2026-01-01 @ 7:20 AM
Study NCT ID:
NCT01743950
Status:
TERMINATED
Last Update Posted:
2025-01-08
First Post:
2012-11-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
Sponsor:
University of Wisconsin, Madison
Organization:
Study Overview
Official Title:
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
Status:
TERMINATED
Status Verified Date:
2025-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
slow accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the efficacy of Pulse Reduced Dose Rate (PRDR) radiation when given in 27 fraction over 5.5 weeks with concurrent bevacizumab followed by adjuvant bevacizumab until time of progression in patients with recurrent high grade gliomas (grade III and grade IV). Patients will be placed in 1 of 4 groups based on their histologic diagnosis and prior exposure to bevacizumab.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| NCI-2012-02775 | REGISTRY | NCI Trial ID | View | |
| 2012-0648 | OTHER | Institutional Review Board | View | |
| 2017-0683 | OTHER | Institutional Review Board | View | |
| A533300 | OTHER | UW Madison | View | |
| SMPH\HUMAN ONCOLOGY\HUMAN ONCO | OTHER | UW Madison | View | |
| Protocol Version 10/14/2020 | OTHER | UW Madison | View |